Note 16 – Related Party Transactions



K. Gary Barnette, the Company’s Chief Scientific Officer, holds a 25% equity interest in a company from which Aspen Park purchased intellectual property assets relating to our Tamsulosin DRS drug candidate in 2016.  We have continuing installment and milestone payment obligations to this company under the purchase agreement.  We did not make any payments to this company during the fiscal year ended September 30, 2018. During the fiscal year ended September 30, 2017, we paid a total of $375,000 to this company.